Tohru Kurosawa

Summary

Affiliation: Meiji Seika Kaisha
Country: Japan

Publications

  1. ncbi request reprint Population pharmacokinetics of tebipenem pivoxil (ME1211), a novel oral carbapenem antibiotic, in pediatric patients with otolaryngological infection or pneumonia
    Nobuo Sato
    Applied Pharmacology Research Labs, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, Kanagawa, Japan
    Drug Metab Pharmacokinet 23:434-46. 2008
  2. ncbi request reprint [Convulsive liability of an oral carbapenem antibiotic, tebipenem pivoxil]
    Yukihiro Yagi
    Applied Pharmacology Research Labs, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd
    Jpn J Antibiot 62:241-52. 2009
  3. ncbi request reprint Suppressive effect of cocoa powder on atherosclerosis in Kurosawa and Kusanagi-hypercholesterolemic rabbits
    Tohru Kurosawa
    Toxicology Laboratory, Pharmaceutical Development Department, Meiji Seika Kaisha, Ltd, Kanagawa, Japan
    J Atheroscler Thromb 12:20-8. 2005
  4. ncbi request reprint Suppressive effects of cacao liquor polyphenols (CLP) on LDL oxidation and the development of atherosclerosis in Kurosawa and Kusanagi-hypercholesterolemic rabbits
    Tohru Kurosawa
    Toxicology Laboratory, Pharmaceutical Development Department, Meiji Seika Kaisha Ltd, 760 Morooka cho, Kohoku Ku, Yokohama 222 8567, Japan
    Atherosclerosis 179:237-46. 2005
  5. ncbi request reprint Active uptake of ulifloxacin from plasma to lung that controls its concentration in epithelial lining fluid
    Makoto Aoki
    Applied Pharmacology Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha Ltd, Yokohama, Japan
    Biol Pharm Bull 32:1095-100. 2009
  6. ncbi request reprint [Pharmacokinetics of tebipenem pivoxil, a novel oral carbapenem antibiotic, in experimental animals]
    Koji Kijima
    Pharmacokinetic Labs, Applied Pharmacology Research Labs, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd
    Jpn J Antibiot 62:214-40. 2009
  7. ncbi request reprint Proposal of membrane transport mechanism of protein-unbound ulifloxacin into epithelial lining fluid determined by improved microdialysis
    Makoto Aoki
    Applied Pharmacology Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, Yokohama, Japan
    Biol Pharm Bull 31:1773-7. 2008
  8. doi request reprint Neuronal expression, cytosolic localization, and developmental regulation of the organic solute carrier partner 1 in the mouse brain
    Kazuyuki Hiratsuka
    Toxicology Laboratory, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, Kanagawa, 230 0074, Japan
    Histochem Cell Biol 135:229-38. 2011
  9. doi request reprint Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: involvement of human OATP family in apical membrane transport
    Kazuhiko Kato
    Applied Pharmacology Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, Yokohama, Japan
    Mol Pharm 7:1747-56. 2010
  10. doi request reprint Physiological models are good tools to predict rat bioavailability of EF5154 prodrugs from in vitro intestinal parameters
    Masahiro Nomoto
    Applied Pharmacology Research Labs, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, 760 Morooka cho, Kohoku Ku, Yokohama 222 8567, Japan
    J Pharm Sci 98:1532-44. 2009

Collaborators

Detail Information

Publications16

  1. ncbi request reprint Population pharmacokinetics of tebipenem pivoxil (ME1211), a novel oral carbapenem antibiotic, in pediatric patients with otolaryngological infection or pneumonia
    Nobuo Sato
    Applied Pharmacology Research Labs, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, Kanagawa, Japan
    Drug Metab Pharmacokinet 23:434-46. 2008
    ..The CL/F of TBPM increased with Ccr, and the Vd/F decreased with age. Based on the results of the present analysis, validity of the presently recommended dosage regimen of TBPM-PI in pediatric patients is discussed...
  2. ncbi request reprint [Convulsive liability of an oral carbapenem antibiotic, tebipenem pivoxil]
    Yukihiro Yagi
    Applied Pharmacology Research Labs, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd
    Jpn J Antibiot 62:241-52. 2009
    ..Accordingly, the risk of occurrence of convulsion related to TBPM-PI administration was low compared to IPM/CS administration, and TBPM-PI was considered to be less potential to induce convulsions in clinical use...
  3. ncbi request reprint Suppressive effect of cocoa powder on atherosclerosis in Kurosawa and Kusanagi-hypercholesterolemic rabbits
    Tohru Kurosawa
    Toxicology Laboratory, Pharmaceutical Development Department, Meiji Seika Kaisha, Ltd, Kanagawa, Japan
    J Atheroscler Thromb 12:20-8. 2005
    ..We consider that antioxidative activity of polyphenols rich in cocoa powder may be a key factor for the anti-atherosclerotic effect...
  4. ncbi request reprint Suppressive effects of cacao liquor polyphenols (CLP) on LDL oxidation and the development of atherosclerosis in Kurosawa and Kusanagi-hypercholesterolemic rabbits
    Tohru Kurosawa
    Toxicology Laboratory, Pharmaceutical Development Department, Meiji Seika Kaisha Ltd, 760 Morooka cho, Kohoku Ku, Yokohama 222 8567, Japan
    Atherosclerosis 179:237-46. 2005
    ..Therefore, CLP suppressed the generation of atherosclerosis, and its antioxidative effect appeared to have an important role in its anti-atherosclerotic activity...
  5. ncbi request reprint Active uptake of ulifloxacin from plasma to lung that controls its concentration in epithelial lining fluid
    Makoto Aoki
    Applied Pharmacology Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha Ltd, Yokohama, Japan
    Biol Pharm Bull 32:1095-100. 2009
    ..We believe our study will contribute to much better understanding of antibiotic efficacy against pathogens which cause pneumonia...
  6. ncbi request reprint [Pharmacokinetics of tebipenem pivoxil, a novel oral carbapenem antibiotic, in experimental animals]
    Koji Kijima
    Pharmacokinetic Labs, Applied Pharmacology Research Labs, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd
    Jpn J Antibiot 62:214-40. 2009
    ..4% and 11.4% of radioactivity was excreted in urine and bile, respectively, by 24 hours after administration. The majority of dosage was excreted out of body by 4 hours after administration...
  7. ncbi request reprint Proposal of membrane transport mechanism of protein-unbound ulifloxacin into epithelial lining fluid determined by improved microdialysis
    Makoto Aoki
    Applied Pharmacology Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, Yokohama, Japan
    Biol Pharm Bull 31:1773-7. 2008
    ..Our MD can help progress in pharmacokinetic-pharmacodynamic analysis of various antibiotics in the case where the concentrations in ELF are not equal to that in plasma...
  8. doi request reprint Neuronal expression, cytosolic localization, and developmental regulation of the organic solute carrier partner 1 in the mouse brain
    Kazuyuki Hiratsuka
    Toxicology Laboratory, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, Kanagawa, 230 0074, Japan
    Histochem Cell Biol 135:229-38. 2011
    ..These results indicate that OSCP1 may have a role in the brain indirectly mediating substrate uptake into the neurons in adult animals...
  9. doi request reprint Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: involvement of human OATP family in apical membrane transport
    Kazuhiko Kato
    Applied Pharmacology Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, Yokohama, Japan
    Mol Pharm 7:1747-56. 2010
    ..These results suggested that TBPM-PI has high intestinal apical membrane permeability due to plural intestinal transport routes, including the uptake transporters such as OATP1A2 and OATP2B1 as well as simple diffusion...
  10. doi request reprint Physiological models are good tools to predict rat bioavailability of EF5154 prodrugs from in vitro intestinal parameters
    Masahiro Nomoto
    Applied Pharmacology Research Labs, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, 760 Morooka cho, Kohoku Ku, Yokohama 222 8567, Japan
    J Pharm Sci 98:1532-44. 2009
    ....
  11. ncbi request reprint New concept and a theoretical consideration of the mechanism-based pharmacokinetics/ pharmacodynamics (PK/PD) modeling for antimicrobial agents
    Nobuo Sato
    Meiji Seika Kaisha, Ltd, Pharmaceutical Research Center, Kanagawa, Japan
    Jpn J Antibiot 61:314-38. 2008
    ....
  12. doi request reprint Intratesticular localization of the organic solute carrier protein, OSCP1, in spermatogenic cells in mice
    Kazuyuki Hiratsuka
    Toxicology Laboratory, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, Kanagawa, Japan
    Mol Reprod Dev 75:1495-504. 2008
    ..These results suggest that mouse testis OSCP1 may indirectly mediate substrate uptake into meiotic and spermiogenic germ cells, within the cytosol...
  13. ncbi request reprint [Pharmacokinetics analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infections]
    Koji Kijima
    Pharmacokinetic Labs, Applied Pharmacology Research Labs, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd
    Jpn J Antibiot 62:143-54. 2009
    ..Changes in the regimen and dosage did not influence the pharmacokinetic properties of TBPM-PI. Pharmacokinetics of TBPM-PI in adult patients with otolaryngological infection were similar to those in healthy subjects...
  14. ncbi request reprint Transporter-mediated hepatic uptake of ulifloxacin, an active metabolite of a prodrug-type new quinolone antibiotic prulifloxacin, in rats
    Yukihiro Yagi
    Toxicology and Pharmacokinetics Research Labs, Pharmaceutical Research Center, Meiji Seika Kaisha Ltd, Yokohama, Japan
    Drug Metab Pharmacokinet 22:350-7. 2007
    ..These results demonstrate that a carrier-mediated transport system which is common to the quinolone antibiotics is involved in the uptake of UFX in the rat liver...
  15. ncbi request reprint Comparative assessment of prurifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia
    Megumi Akita
    Toxicology Laboratory, Pharmaceutical Development Department, Meiji Seika Kaisha, Ltd, 760 Morooka cho, Kohoku Ku, Yokohama 222 8567, Japan
    J Toxicol Sci 29:63-71. 2004
    ..These findings suggested that LVFX and UFX were less potent than SPFX and GFLX in prolonging the QT interval and inducing life-threatening arrhythmias...
  16. ncbi request reprint ME3738 protects against lithocholic acid-induced hepatotoxicity, which is associated with enhancement of biliary bile acid and cholesterol output
    Masahiro Nomoto
    Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, Aramaki, Aoba ku, Sendai 980 8578, Japan
    Eur J Pharmacol 574:192-200. 2007
    ..These results suggest that ME3738 protects against bile acid-induced hepatotoxicity through increased biliary bile acid output that is not related to bile acid metabolism but associated with cholesterol output...